S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

Agios Pharmaceuticals Stock Forecast, Price & News

-0.11 (-0.35%)
(As of 01/19/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
576,264 shs
Average Volume
386,067 shs
Market Capitalization
$1.69 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Agios Pharmaceuticals logo

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.


4 Biotechs That Were Winners at ASH
January 3, 2022 |  fool.com
Agios Appoints Richa Poddar as Chief Commercial Officer
November 15, 2021 |  finance.yahoo.com
What Wall Street expects from Agios Pharmaceuticals's earnings
November 4, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$203.20 million
Book Value
$5.76 per share


Net Income
$-327.37 million
Pretax Margin




Free Float
Market Cap
$1.69 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.81 out of 5 stars

Medical Sector

839th out of 1,415 stocks

Pharmaceutical Preparations Industry

405th out of 682 stocks

Analyst Opinion: 3.1Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

Is Agios Pharmaceuticals a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Agios Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGIO, but not buy additional shares or sell existing shares.
View analyst ratings for Agios Pharmaceuticals
or view top-rated stocks.

How has Agios Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AGIO shares have decreased by 24.1% and is now trading at $31.03.
View which stocks have been most impacted by COVID-19

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Agios Pharmaceuticals

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, topping the consensus estimate of ($1.57) by $0.09. During the same period last year, the firm earned ($1.43) earnings per share.
View Agios Pharmaceuticals' earnings history

What price target have analysts set for AGIO?

8 equities research analysts have issued 12-month price objectives for Agios Pharmaceuticals' shares. Their forecasts range from $39.00 to $95.00. On average, they expect Agios Pharmaceuticals' share price to reach $59.00 in the next twelve months. This suggests a possible upside of 90.1% from the stock's current price.
View analysts' price targets for Agios Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the following people:
  • Jacqualyn A. Fouse, Chief Executive Officer & Director
  • Jonathan Prim Biller, CFO, Head-Legal & Corporate Affairs
  • Clive Patience, Executive Vice President-Technical Operations
  • Sarah Gheuens, Chief Medical Officer
  • Bruce Car, Chief Scientific Officer

What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals CEO Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among Agios Pharmaceuticals' employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $31.03.

How much money does Agios Pharmaceuticals make?

Agios Pharmaceuticals has a market capitalization of $1.69 billion and generates $203.20 million in revenue each year. The biopharmaceutical company earns $-327.37 million in net income (profit) each year or $22.57 on an earnings per share basis.

How many employees does Agios Pharmaceuticals have?

Agios Pharmaceuticals employs 562 workers across the globe.

What is Agios Pharmaceuticals' official website?

The official website for Agios Pharmaceuticals is www.agios.com.

Where are Agios Pharmaceuticals' headquarters?

Agios Pharmaceuticals is headquartered at 88 SIDNEY STREET, CAMBRIDGE MA, 02139.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at [email protected].

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.